Skip to main content

Day: June 6, 2021

iSIGN Media Selected as Exclusive Technology Platform for Proof-of-Concept Installation for Contact Tracing in Airports and Municipally Managed Public Spaces

TORONTO, June 06, 2021 (GLOBE NEWSWIRE) — iSIGN Media Solutions Inc. (“iSIGN” or “Company”) (TSX-V: ISD) (OTC: ISDSF), a leading provider of interactive mobile proximity marketing and public security alert solutions announced that the Company has been selected by SIMBL Business Enablement Inc. as the Exclusive Technology Platform in an on-going proof-of-concept (“POC”) contract between SIMBL Business Enablement Inc. and Innovation Solutions Canada (“ISC”), with the paid POC deployment currently underway at Prince George Airport in British Columbia. This POC program, called Passive Historical Aggregate Contact Tracing (“PHACT”) has been approved and vetted by the ISC. PHACT has been designed from the outset to address the shortcomings of traditional app-based systems.   The platform utilizes iSIGN’s proprietary technology to overcome...

Continue reading

Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting

Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study Early Intervention with Lifileucel Following Progression on Anti-PD-1 Therapy May Maximize Benefit ASCO Update Conference Call and Webcast at 12 p.m. ET Today SAN CARLOS, Calif., June 06, 2021 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced updated clinical data for lifileucel from Cohort 2 in the C-144-01 clinical study in patients with advanced melanoma. The data were presented in an oral presentation at the ASCO 2021 Annual Meeting. Omid Hamid, M.D., Chief of Research/Immuno-Oncology, The Angeles Clinic & Research Institute, stated, “Anti-PD-1 therapy is a mainstay class of treatment offering...

Continue reading

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria1 – a key risk predictor in kidney disease progression2Iptacopan also showed a trend toward stabilization of kidney function1; Phase III clinical trial APPLAUSE is underwayThere are no currently approved treatments for IgAN – a rare and often progressive kidney disease that mainly affects young adults and can progress to kidney failure3-7Iptacopan is in development for several complement-driven renal diseases (CDRDs), including IgAN and C3 glomerulopathy (C3G), and the blood disorder paroxysmal nocturnal hemoglobinuria (PNH), targeting a key driver of these diseasesBasel, June 06, 2021 — Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023)...

Continue reading

Enjoy Low and Competitive lap Loan Interest Rate

If you are looking for funds to take your business to new heights, you do not need to worry about the tedious eligibility criteria or heavy documentation. You can apply for a loan against property and enjoy high loan amount at low interest rate. Hero FinCorp is a reliable lender in the country with a presence across every corner of India. They offer low lap loan interest rate and will ensure that the loan serves your purpose. Hero FinCorp has a stronghold on the industry and is considered as one of the best today. You can use your commercial or residential property for the purpose of the loan. It can be in use, rented or leased. The loan application procedure is simple and hassle free. Hero FinCorp strives to help individuals turn their dreams into a reality and no matter the size or type of business you own, you are eligible for the loan....

Continue reading

Toga Limited’s Social Media App Yippi Launches “Yipps Wanted” Program to Provide a Seamless Business Solutions for Merchants

PETALING JAYA, Malaysia, June 05, 2021 (GLOBE NEWSWIRE) — Toga Limited’s (OTC:TOGL) social media mobile app, Yippi, launches “Yipps Wanted” program, an end-to-end e-commerce platform solution, aimed at assisting small medium businesses (SMBs) and enterprises (SMEs) in Malaysia to increase the number of customers and drive traffic to their physical and or online stores. The “Yipps Wanted” program is available in a mini program on the Yippi platform, and a merchant mobile application. As a mini program, “Yipps Wanted” offers customers and merchants chances to win prizes when they spend Yipps – the virtual reward points that can be redeemed in transactions conducted through the Yippi app. Merchants can also offer instant rewards to walk-in customers who spend in their stores simply by scanning their Yippi QR code via the mini program....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.